epiglucan and Dermatitis--Allergic-Contact

The clinical efficiency of mitigating contact dermatitis with a Ginkgo biloba extract and carboxymethyl-beta-1,3-glucan formulation was investigated in a double-blind versus placebo study using 22 subjects (Caucasian women aged 22-55 years) with allergic contact dermatitis from various substances in the European standard series. The formulation was applied to intact skin 2X a day for 2 weeks ("in use" application) prior to a single application of a selected contact allergen under a Finn Chamber for 24 h. Readings were carried out in a blind study by a dermatologist 2 and 3 days after patch removal. Representative photographs were taken of treated, placebo and untreated test areas. 68.2% of the panelists showed significantly reduced skin reactivity (p = 0.037*) on the treated site 2 days after patch removal, versus untreated and/or placebo sites. This finding indicates that the Ginkgo biloba/carboxymethyl-beta-1,3-glucan formulation can mitigate against allergic contact dermatitis.

Topics: Adult; beta-Glucans; Dermatitis, Allergic Contact; Double-Blind Method; Drug Combinations; Female; Flavonoids; Free Radical Scavengers; Ginkgo biloba; Glucans; Humans; Middle Aged; Ointments; Patch Tests; Plant Extracts; Skin Care; Treatment Outcome

Topics: Anti-Allergic Agents; beta-Glucans; Dermatitis, Allergic Contact; Drug Therapy, Combination; Ginkgo biloba; Glucans; Humans; Phytotherapy; Plant Extracts; Plants, Medicinal